GLP-1 agonists are injectable or oral medicines that mimic the glucagon-like peptide-1 hormone to improve blood-glucose control and support weight management. Starting therapy requires a structured medical pathway that begins with eligibility screening and ends with an individualized titration plan. Patients and clinicians work together to confirm the diagnosis, review contraindications, set expectations for side effects, and schedule follow-up labs and visits. This article outlines the exact sequence of actions that turn a prescription decision into a safe, monitored treatment start.
How to Start GLP-1
Begin with a confirmed clinical indication such as type 2 diabetes or obesity with comorbidities. Your clinician reviews current medications, kidney and liver function, and history of pancreatitis or medullary thyroid carcinoma. Once cleared, the first dose is chosen at the lowest available strength to reduce gastrointestinal side effects. Injection training or oral-administration instructions are provided during the same visit, and a follow-up appointment is booked for two to four weeks later.
How to Start GLP-1 0
The initial phase uses the lowest strength, often labeled as the starter dose. Patients learn proper storage, injection-site rotation, and timing relative to meals. A symptom log tracks nausea, appetite changes, and any abdominal pain. The clinician adjusts the dose only after confirming tolerability, typically at the first follow-up. This zero-to-low escalation step protects against early discontinuation caused by side effects.
Why It Matters
A deliberate start reduces the risk of severe nausea, dehydration, or acute pancreatitis. It also establishes baseline kidney-function and thyroid-marker values so any later changes can be correctly attributed. Structured initiation improves long-term adherence and allows early detection of rare but serious adverse events.
How to Begin Treatment: Practical Steps
- Schedule a visit with an endocrinologist, obesity-medicine specialist, or primary-care provider experienced in GLP-1 agonists.
- Complete required labs: renal panel, liver enzymes, HbA1c, and calcitonin if indicated.
- Receive device training and written instructions on missed-dose handling.
- Set calendar reminders for weekly injections and the next lab draw.
- Report persistent vomiting or severe abdominal pain immediately.
Starter-Dose Monitoring Checklist
- Record weight and blood glucose (or continuous-glucose-monitor data) daily for the first 14 days
- Note any nausea on a 0–10 scale each evening
- Confirm injection sites remain free of redness or lumps
- Schedule a 2-week phone or in-person check-in
FAQ
What side effects should I expect in the first month?
Most people experience mild-to-moderate nausea, reduced appetite, or occasional diarrhea that improves within two to three weeks. Staying hydrated, eating smaller meals, and avoiding high-fat foods usually lessen symptoms. Severe or persistent vomiting requires prompt medical review.
How soon will I notice changes in appetite or weight?
Appetite reduction often appears within the first one to two weeks. Measurable weight loss typically begins after the dose reaches the therapeutic range, usually between weeks four and eight, provided diet and activity habits are also adjusted.
Can I start a GLP-1 agonist if I take other diabetes medicines?
Yes, but your clinician may lower the dose of sulfonylureas or insulin to avoid hypoglycemia. A full medication review occurs before the first prescription is written.
Last updated: October 2, 2026